0001104659-16-160304.txt : 20161202 0001104659-16-160304.hdr.sgml : 20161202 20161202093217 ACCESSION NUMBER: 0001104659-16-160304 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20161202 DATE AS OF CHANGE: 20161202 EFFECTIVENESS DATE: 20161202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TETRALOGIC PHARMACEUTICALS Corp CENTRAL INDEX KEY: 0001361248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-36208 FILM NUMBER: 162029933 BUSINESS ADDRESS: STREET 1: P.O. BOX 1305 CITY: PAOLI STATE: NY ZIP: 19301 BUSINESS PHONE: 610-889-9900 MAIL ADDRESS: STREET 1: P.O. BOX 1305 CITY: PAOLI STATE: NY ZIP: 19301 FORMER COMPANY: FORMER CONFORMED NAME: TETRALOGIC PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20060501 15-12B 1 a16-21945_31512b.htm 15-12B

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

 

Commission File Number  

001-36208

 

TetraLogic Pharmaceuticals Corporation

(Exact name of registrant as specified in its charter)

 

P.O. Box 1306 Paoli, PA 19301

(808) 554-7456

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

 

Rule 12g-4(a)(1)

x

 

 

 

 

 

Rule 12g-4(a)(2)

o

 

 

 

 

 

Rule 12h-3(b)(1)(i)

x

 

 

 

 

 

Rule 12h-3(b)(1)(ii)

o

 

 

 

 

 

Rule 15d-6

o

 

 

 

 

 

 

 

 

 

 

 

 

Approximate number of holders of record as of the certification or notice date: 122.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, TetraLogic Pharmaceuticals Corporation has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

 

 

 

 

 

 

Date:

December 2, 2016

 

TetraLogic Pharmaceuticals Corporation.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

By:

/s/ Richard L. Sherman

 

 

 

 

Name:

Richard L. Sherman

 

 

 

 

Title:

Senior Vice President, Strategic Transactions, General Counsel and Secretary